Evidence map›Paper›PMID 40249615›Full record

Observational studyJAMA network open2025

Genetic and Nongenetic Risk Factors for Breast Cancer Risk Estimation.

Wenji Guo, James L Li, Julian McClellan, Atara Ntekim, Oladosu Ojengbede, Temidayo Ogundiran, Abayomi Odetunde, John Obafunwa, Abiodun Popoola, Paul Ndom and 7 more

Erratum issuedAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Error in the Discussion.JAMA network open · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Wenji GuoSection of Hematology and Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois.
James L LiDepartment of Public Health Sciences, The University of Chicago, Chicago, Illinois.
Julian McClellanDepartment of Public Health Sciences, The University of Chicago, Chicago, Illinois.
Atara NtekimDepartment of Radiation Oncology, College of Medicine, University of Ibadan, Ibadan, Nigeria.
Oladosu OjengbedeCenter for Population and Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Nigeria.
Temidayo OgundiranDepartment of Surgery, College of Medicine, University of Ibadan, Ibadan, Nigeria.
Abayomi OdetundeInstitute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Nigeria.
John ObafunwaDepartment of Pathology and Forensic Medicine, Lagos State University Teaching Hospital, Lagos, Nigeria.
Abiodun PopoolaDepartment of Radiation and Clinical Oncology, Lagos State University Teaching Hospital, Lagos, Nigeria.
Paul NdomYaounde General Hospital, Yaounde, Cameroon.
Antony GakwayaDepartment of Surgery, King Ceasor University, Kampala, Uganda.
Nilanjan ChatterjeeDepartment of Biostatistics, Johns Hopkins University, Baltimore, Maryland.
Elisabeth SveenSection of Hematology and Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois.
Toshio F YoshimatsuSection of Hematology and Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois.
Yonglan ZhengSection of Hematology and Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois.
Olufunmilayo I OlopadeSection of Hematology and Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois.
Dezheng HuoSection of Hematology and Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois.

Funding

Pilot Program CoreP30ES027792 · NIEHS · UNIVERSITY OF CHICAGO · PI Gokhan M. Mutlu, Gail S Prins · 2017 to 2026
$13.6M
BASIC RESEARCH TRAINING IN MEDICAL ONCOLOGYT32CA009566 · NCI · UNIVERSITY OF CHICAGO · PI OLUFUNMILAYO F. OLOPADE · 1987 to 2026
$10.5M
Polygenic Risk Prediction of Breast Cancer for Women of African DescentR01CA228198 · NCI · UNIVERSITY OF CHICAGO · PI Dezheng Huo · 2018 to 2026
$3.9M
Etiology and Genomics of Breast Cancer Progression in Women of African AncestryR01MD013452 · NIMHD · UNIVERSITY OF CHICAGO · PI HUO, DEZHENG, OLOPADE, OLUFUNMILAYO F. · 2019 to 2023
$2.8M
Multifactoral breast cancer risk prediction accounting for ethnic and tumor diversityU01CA249866 · NCI · JOHNS HOPKINS UNIVERSITY · PI CHATTERJEE, NILANJAN · 2020 to 2023
$2.3M
Statistical Methods for Data Integration and Applications to Genome-wide Association StudiesR01HG013137 · NHGRI · JOHNS HOPKINS UNIVERSITY · PI Nilanjan Chatterjee · 2024 to 2026
$843k
Statistical Methods for Data Integration and Applications to Genome-wide Association StudiesR56HG013137 · NHGRI · JOHNS HOPKINS UNIVERSITY · PI CHATTERJEE, NILANJAN · 2023 to 2023
$290k
NCI NIH HHS R01 CA228198NCI NIH HHS T32 CA009566NCI NIH HHS U01 CA249866NHGRI NIH HHS R01 HG013137NHGRI NIH HHS R56 HG013137NIEHS NIH HHS P30 ES027792NIMHD NIH HHS R01 MD013452
6 · The paper itself

Abstract

Importance: Most breast cancers in Africa are diagnosed at advanced stages. Improved risk prediction tools to optimize screening and earlier diagnosis are urgently needed. Objective: To build a comprehensive breast cancer risk estimation model by integrating a polygenic risk score (PRS), pathogenic variants (PVs) in high- or moderate-penetrance genes, and a questionnaire-based risk calculator. Design, Setting, and Participants: This multicenter case-control study initially enrolled women in Nigeria in 1998 and expanded to Cameroon and Uganda in 2011; enrollment ended in 2018. Women with breast cancer (hereafter cases) were enrolled through hospital oncology units, whereas women without breast cancer (hereafter controls) were recruited from other outpatient clinics and the community. Participants whose genetic data were used in PRS development were excluded from the development of the comprehensive breast cancer risk estimation model. Analyses were performed from September 2023 to January 2025. Exposures: Lifetime absolute risk estimation models that integrated a PRS only (previously developed using data from women of African ancestry and European ancestry), PRS plus PVs in high- or moderate-penetrance genes (BRCA1, BRCA2, PALB2, ATM, CHEK2, TP53, BARD1, RAD51C, and RAD51D), epidemiologic risk factors only (ascertained from NBCS questionnaires), and a combined model containing these 3 components. Main Outcomes and Measures: Lifetime absolute risk of breast cancer was estimated, accounting for an association between family history and genetic factors. Participants' lifetime estimated absolute risk was categorized by the following risk thresholds: lower than 3%, 3%, 5%, and 10% or higher. Results: A total of 1686 women, of whom 996 were cases (mean [SD] age at enrollment, 49.5 [12.2] years) and 690 were controls (mean [SD] age at enrollment, 41.5 [13.8] years), were included in the main analyses. The age-adjusted area under the receiver operating characteristic curve (AUROC) was 0.579 (95% CI, 0.549-0.610) for the PRS only model and 0.609 (95% CI, 0.579-0.638) for the PRS plus PV model. In the combined model containing both genetic and nongenetic risk factors, age-adjusted AUROC increased to 0.723 (95% CI, 0.698-0.748). Using a threshold of 10% or higher lifetime absolute risk, the combined model classified 12.0% of cases (120) as high risk compared with 3.7% of cases (37) using the epidemiologic factors only model and 5.0% of cases (50) using the PRS plus PV model. Conclusions and Relevance: In this case-control study, a breast cancer risk estimation model was developed that combines genetic and nongenetic factors and refines a previous model that includes epidemiologic risk factors. Further development and validation of this model are necessary to advance breast cancer risk assessment in sub-Saharan Africa.

Indexed as

Breast NeoplasmsGenetic Predisposition to DiseaseAdultCameroonCase-Control StudiesFemaleHumansMiddle AgedNigeriaRisk AssessmentRisk FactorsUganda

Identifiers

PMID40249615
PMCPMC12008756

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.